[The effectiveness of Ticagrelor does not depend on CYP2C19 gene polymorphism and ABCB1: results of a genetic analysis of the study PLATO].
E N
EN
Dankovtseva
B A
BA
Sidorenko
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D006801:Humans; D011110:Polymorphism, Genetic; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D000077486:Ticagrelor
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D058921:Purinergic P2Y Receptor Antagonists; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D000077486:Ticagrelor; D000241:Adenosine